Clifford Swan Investment Counsel LLC Amgen Inc Transaction History

Clifford Swan Investment Counsel LLC

$2.78 Billion
Q3 2024

A detailed history of Clifford Swan Investment Counsel LLC transactions in Amgen Inc stock. As of the latest transaction made, Clifford Swan Investment Counsel LLC holds 39,150 shares of AMGN stock, worth $11.5 Million. This represents 0.45% of its overall portfolio holdings.

Number of Shares

39,150

Previous 39,683 1.34%

Holding current value

$11.5 Million

Previous $12.4 Million 1.74%

% of portfolio

0.45%

Previous 0.47%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$309.38 - $337.38 $164,899 - $179,823	-533 Reduced 1.34%	39,150 $12.6 Million
Q2 2024 Aug 06, 2024	SELL	$262.75 - $319.31 $10,247 - $12,453	-39 Reduced 0.1%	39,683 $12.4 Million
Q1 2024 Apr 16, 2024	SELL	$268.87 - $324.56 $103,783 - $125,280	-386 Reduced 0.96%	39,722 $11.3 Million
Q4 2023 Feb 06, 2024	SELL	$255.7 - $288.46 $78,499 - $88,557	-307 Reduced 0.76%	40,108 $11.6 Million
Q3 2023 Nov 09, 2023	SELL	$218.65 - $271.46 $118,289 - $146,859	-541 Reduced 1.32%	40,415 $10.9 Million
Q2 2023 Aug 03, 2023	SELL	$214.27 - $253.37 $41,354 - $48,900	-193 Reduced 0.47%	40,956 $9.09 Million
Q1 2023 May 05, 2023	SELL	$225.79 - $275.2 $48,544 - $59,168	-215 Reduced 0.52%	41,149 $9.95 Million
Q4 2022 Feb 02, 2023	SELL	$229.03 - $291.01 $916 - $1,164	-4 Reduced 0.01%	41,364 $10.9 Million
Q3 2022 Nov 04, 2022	SELL	$224.46 - $253.15 $57,012 - $64,300	-254 Reduced 0.61%	41,368 $9.32 Million
Q2 2022 Aug 04, 2022	BUY	$230.71 - $256.74 $14,073 - $15,661	61 Added 0.15%	41,622 $10.1 Million
Q1 2022 May 03, 2022	SELL	$219.27 - $242.57 $952,508 - $1.05 Million	-4,344 Reduced 9.46%	41,561 $10.1 Million
Q4 2021 Feb 11, 2022	SELL	$198.88 - $227.6 $88,700 - $101,509	-446 Reduced 0.96%	45,905 $10.3 Million
Q3 2021 Nov 02, 2021	SELL	$212.27 - $248.7 $77,478 - $90,775	-365 Reduced 0.78%	46,351 $9.86 Million
Q2 2021 Aug 05, 2021	SELL	$233.58 - $259.14 $392,180 - $435,096	-1,679 Reduced 3.47%	46,716 $10.7 Million
Q1 2021 May 07, 2021	SELL	$221.91 - $258.6 $258,081 - $300,751	-1,163 Reduced 2.35%	48,395 $12 Million
Q4 2020 Feb 11, 2021	SELL	$216.38 - $257.67 $530,131 - $631,291	-2,450 Reduced 4.71%	49,558 $11.4 Million
Q3 2020 Oct 30, 2020	SELL	$234.65 - $260.95 $862,104 - $958,730	-3,674 Reduced 6.6%	52,008 $13.2 Million
Q2 2020 Aug 06, 2020	SELL	$197.81 - $242.74 $137,477 - $168,704	-695 Reduced 1.23%	55,682 $13.1 Million
Q1 2020 Apr 09, 2020	BUY	$182.24 - $241.7 $293,406 - $389,137	1,610 Added 2.94%	56,377 $11.4 Million
Q4 2019 Jan 30, 2020	SELL	$189.21 - $243.2 $218,537 - $280,896	-1,155 Reduced 2.07%	54,767 $13.2 Million
Q3 2019 Nov 12, 2019	SELL	$174.11 - $208.62 $16,888 - $20,236	-97 Reduced 0.17%	55,922 $10.8 Million
Q2 2019 Aug 13, 2019	SELL	$166.7 - $195.41 $63,846 - $74,842	-383 Reduced 0.68%	56,019 $10.3 Million
Q1 2019 May 14, 2019	SELL	$180.87 - $203.88 $358,303 - $403,886	-1,981 Reduced 3.39%	56,402 $10.7 Million
Q4 2018 Feb 13, 2019	SELL	$178.4 - $208.25 $473,295 - $552,487	-2,653 Reduced 4.35%	58,383 $11.4 Million
Q3 2018 Nov 14, 2018	SELL	$185.29 - $208.89 $263,667 - $297,250	-1,423 Reduced 2.28%	61,036 $12.7 Million
Q2 2018 Aug 13, 2018	SELL	$166.05 - $186.51 $4,483 - $5,035	-27 Reduced 0.04%	62,459 $11.5 Million
Q1 2018 May 09, 2018	BUY	$169.43 - $198.0 $64,044 - $74,844	378 Added 0.61%	62,486 $10.7 Million
Q4 2017 Feb 09, 2018	BUY	$168.79 - $188.59 $286,099 - $319,660	1,695 Added 2.81%	62,108 $10.8 Million
Q3 2017 Nov 13, 2017	BUY	$167.29 - $191.0 $64,406 - $73,535	385 Added 0.64%	60,413 $11.3 Million
Q2 2017 Aug 11, 2017	BUY	N/A	60,028	60,028 $10.3 Million

Others Institutions Holding AMGN

# of Institutions

3,123

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $157B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Clifford Swan Investment Counsel LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clifford Swan Investment Counsel LLC with notifications on news.

Account

Clifford Swan Investment Counsel LLC Amgen Inc Transaction History